{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:25:39Z","timestamp":1762608339923},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00108-021-01059-0","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T12:02:32Z","timestamp":1624017752000},"page":"827-840","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostik und Therapie von statinassoziierten Muskelsymptomen"],"prefix":"10.1007","volume":"62","author":[{"given":"Ursula","family":"Kassner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Spira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Buchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bobbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Gazzerro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Hollstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Spuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"1059_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrd1112","volume":"2","author":"JA Tobert","year":"2003","unstructured":"Tobert\u00a0JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517\u2013526","journal-title":"Nat Rev Drug Discov"},{"key":"1059_CR2","volume-title":"Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000\u20132016","year":"2016","unstructured":"WHO (Hrsg) (2016) Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000\u20132016. World Health Organization, Geneva"},{"key":"1059_CR3","first-page":"748","volume":"112","author":"U Laufs","year":"2015","unstructured":"Laufs\u00a0U, Scharnagl\u00a0H, Halle\u00a0M, Windler\u00a0E, Endres\u00a0M, M\u00e4rz\u00a0W (2015) Behandlungsoptionen bei Statin-assoziierten Muskelbeschwerden. Dtsch Arztebl Int 112:748\u2013755","journal-title":"Dtsch Arztebl Int"},{"key":"1059_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.atherosclerosis.2018.08.050","volume":"277","author":"N Schmidt","year":"2018","unstructured":"Schmidt\u00a0N, Dressel\u00a0A, Grammer\u00a0TB, Gouni-Berthold\u00a0I, Julius\u00a0U, Kassner\u00a0U, Klose\u00a0G, K\u00f6nig\u00a0C, Koenig\u00a0W, Otte\u00a0B, Parhofer\u00a0KG, Reinhard\u00a0W, Schatz\u00a0U, Schunkert\u00a0H, Steinhagen-Thiessen\u00a0E, Vogt\u00a0A, Laufs\u00a0U, M\u00e4rz\u00a0W (2018) Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: the CaReHigh Registry. Atherosclerosis 277:314\u2013322","journal-title":"Atherosclerosis"},{"key":"1059_CR5","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M\u2011R, Tokgozoglu L, Wiklund O, Mueller C, Drexel H, Aboyans V, Corsini A, Doehner W, Farnier M, Gigante B, Kayikcioglu M, Krstacic G, Lambrinou E, Lewis BS, Masip J, Moulin P, Petersen S, Petronio AS, Piepoli MF, Pint\u00f3 X, R\u00e4ber L, Ray KK, Reiner \u017d, Riesen WF, Roffi M, Schmid J\u2011P, Shlyakhto E, Simpson IA, Stroes E, Sudano I, Tselepis AD, Viigimaa M, Vindis C, Vonbank A, Vrablik M, Vrsalovic M, Zamorano JL, Collet J\u2011P, Koskinas KC, Casula M, Badimon L, John Chapman M, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M\u2011R, Tokgozoglu L, Wiklund O, Windecker S, Aboyans V, Baigent C, Collet J\u2011P, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, J\u00fcni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Nibouche D, Zelveian PH, Siostrzonek P, Najafov R, Van De Borne P, Pojskic B, Postadzhiyan A, Kypris L, \u0160pinar J, Larsen ML, Eldin HS, Viigimaa M, Strandberg TE, Ferri\u00e8res J, Agladze R, Laufs U, Rallidis L, Bajnok L, Gudj\u00f3nsson T, Maher V, Henkin Y, Gulizia MM, Mussagaliyeva A, Bajraktari G, Kerimkulova A, Latkovskis G, Hamoui O, Slapikas R, Visser L, Dingli P, Ivanov V, Boskovic A, Nazzi M, Visseren F, Mitevska I, Retterst\u00f8l K, Jankowski P, Fontes-Carvalho R, Gaita D, Ezhov M, Foscoli M, Giga V, Pella D, Fras Z, De Isla LP, Hagstr\u00f6m E, Lehmann R, Abid L, Ozdogan O, Mitchenko O, Patel RS: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020;41:111\u2013188","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"1059_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","volume":"266","author":"AK Gitt","year":"2017","unstructured":"Gitt\u00a0AK, Lautsch\u00a0D, Ferri\u00e8res\u00a0J, De Ferrari\u00a0GM, Vyas\u00a0A, Baxter\u00a0CA, Bash\u00a0LD, Ashton\u00a0V, Horack\u00a0M, Almahmeed\u00a0W, Chiang\u00a0F\u2011T, Poh\u00a0KK, Brudi\u00a0P, Ambegaonkar\u00a0B (2017) Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study II. Atherosclerosis 266:158\u2013166","journal-title":"Atherosclerosis"},{"key":"1059_CR7","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMc2031173","volume":"383","author":"FA Wood","year":"2020","unstructured":"Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP (2020) N\u2011of\u20111 trial of a\u00a0Statin, placebo, or no treatment to assess side effects. N\u00a0Engl J Med 383:2182\u20132184. https:\/\/doi.org\/10.1056\/NEJMc2031173","journal-title":"N\u00a0Engl J Med"},{"key":"1059_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-152-7-201004060-00025","volume":"152","author":"H Knoblauch","year":"2010","unstructured":"Knoblauch\u00a0H, Schoewel\u00a0V, Rosada\u00a0A, Spuler\u00a0S, Kress\u00a0W (2010) Another side to Statin-related side effects. Ann Intern Med 152:478\u2013479","journal-title":"Ann Intern Med"},{"key":"1059_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker\u00a0BA, Capizzi\u00a0JA, Grimaldi\u00a0AS, Clarkson\u00a0PM, Cole\u00a0SM, Keadle\u00a0J, Chipkin\u00a0S, Pescatello\u00a0LS, Simpson\u00a0K, White\u00a0CM, Thompson\u00a0PD (2013) Effect of Statins on skeletal muscle function. Circulation 127:96\u2013103","journal-title":"Circulation"},{"key":"1059_CR10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"DJ Graham","year":"2004","unstructured":"Graham\u00a0DJ (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585","journal-title":"JAMA"},{"key":"1059_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.drudis.2016.09.001","volume":"22","author":"DM Muntean","year":"2017","unstructured":"Muntean\u00a0DM, Thompson\u00a0PD, Catapano\u00a0AL, Stasiolek\u00a0M, Fabis\u00a0J, Muntner\u00a0P, Serban\u00a0MC, Banach\u00a0M (2017) Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 22:85\u201396","journal-title":"Drug Discov Today"},{"key":"1059_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","volume":"114","author":"LR Brunham","year":"2018","unstructured":"Brunham\u00a0LR, Baker\u00a0S, Mammen\u00a0A, Mancini\u00a0GBJ, Rosenson\u00a0RS (2018) Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res 114:1073\u20131081","journal-title":"Cardiovasc Res"},{"key":"1059_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-2350-12-136","volume":"12","author":"PC Santos","year":"2011","unstructured":"Santos\u00a0PC, Soares\u00a0RA, Nascimento\u00a0RM, Machado-Coelho\u00a0GL, Mill\u00a0JG, Krieger\u00a0JE, Pereira\u00a0AC (2011) SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a\u00a0high risk ethnic group. BMC Med Genet 12:136","journal-title":"BMC Med Genet"},{"key":"1059_CR14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","volume":"54","author":"D Voora","year":"2009","unstructured":"Voora\u00a0D, Shah\u00a0SH, Spasojevic\u00a0I, Ali\u00a0S, Reed\u00a0CR, Salisbury\u00a0BA, Ginsburg\u00a0GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J\u00a0Am Coll Cardiol 54:1609\u20131616","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/pds.1866","volume":"19","author":"ML Becker","year":"2010","unstructured":"Becker\u00a0ML, Visser\u00a0LE, van Schaik\u00a0RH, Hofman\u00a0A, Uitterlinden\u00a0AG, Stricker\u00a0BH (2010) Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 19:75\u201381","journal-title":"Pharmacoepidemiol Drug. Saf."},{"key":"1059_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang\u00a0D, Guo\u00a0Y, Wrighton\u00a0SA, Cooke\u00a0GE, Sadee\u00a0W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics\u00a0J 11:274\u2013286","journal-title":"Pharmacogenomics J"},{"key":"1059_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.amjcard.2003.08.078","volume":"93","author":"K Kajinami","year":"2004","unstructured":"Kajinami\u00a0K, Brousseau\u00a0ME, Ordovas\u00a0JM, Schaefer\u00a0EJ (2004) CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93:104\u2013107","journal-title":"Am J Cardiol"},{"key":"1059_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mus.20871","volume":"36","author":"G Rua\u00f1o","year":"2007","unstructured":"Rua\u00f1o\u00a0G, Thompson\u00a0PD, Windemuth\u00a0A, Seip\u00a0RL, Dande\u00a0A, Sorokin\u00a0A, Kocherla\u00a0M, Smith\u00a0A, Holford\u00a0TR, Wu\u00a0AH (2007) Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 36:329\u2013335","journal-title":"Muscle Nerve"},{"key":"1059_CR19","unstructured":"www.snpedia.com. Zugegriffen: 22.10.2020"},{"key":"1059_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/bcpt.12482","volume":"118","author":"M-L Ovesj\u00f6","year":"2016","unstructured":"Ovesj\u00f6\u00a0M\u2011L, Skilving\u00a0I, Bergman\u00a0P, Rane\u00a0A, Ekstr\u00f6m\u00a0L, Bj\u00f6rkhem-Bergman\u00a0L (2016) Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of Statin-induced myopathy. Basic Clin Pharmacol Toxicol 118:214\u2013218","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1059_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","volume":"215","author":"A Gupta","year":"2011","unstructured":"Gupta\u00a0A, Thompson\u00a0PD (2011) The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 215:23\u201329","journal-title":"Atherosclerosis"},{"key":"1059_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","volume":"374","author":"AL Mammen","year":"2016","unstructured":"Mammen\u00a0AL (2016) Statin-associated autoimmune myopathy. N\u00a0Engl J Med 374:664\u2013669","journal-title":"N Engl J Med"},{"key":"1059_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","volume":"99","author":"M Banach","year":"2015","unstructured":"Banach\u00a0M, Serban\u00a0C, Ursoniu\u00a0S, Rysz\u00a0J, Muntner\u00a0P, Toth\u00a0PP, Jones\u00a0SR, Rizzo\u00a0M, Glasser\u00a0SP, Watts\u00a0GF, Blumenthal\u00a0RS, Lip\u00a0GY, Mikhailidis\u00a0DP, Sahebkar A: (2015) Statin therapy and plasma coenzyme Q10 concentrations-\u2014a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 99:329\u2013336","journal-title":"Pharmacol Res"},{"issue":"1","key":"1059_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","volume":"78","author":"H Paiva","year":"2005","unstructured":"Paiva H, Thelen K, Coster R, Smet J, Paepe B, Mattila K, Laakso J, Lehtimaki T, Vonbergmann K, Lutjohann D (2005) High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 78(1):60\u201368. https:\/\/doi.org\/10.1016\/j.clpt.2005.03.006","journal-title":"Clin Pharmacol Ther"},{"key":"1059_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32741","volume-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","author":"J-I Hanai","year":"2007","unstructured":"Hanai\u00a0J\u2011I, Cao\u00a0P, Tanksale\u00a0P, Imamura\u00a0S, Koshimizu\u00a0E, Zhao\u00a0J, Kishi\u00a0S, Yamashita\u00a0M, Phillips\u00a0PS, Sukhatme\u00a0VP, Lecker\u00a0SH (2007) The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity"},{"key":"1059_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1517\/14740338.2011.540568","volume":"10","author":"TT Abd","year":"2011","unstructured":"Abd\u00a0TT, Jacobson\u00a0TA (2011) Statin-induced myopathy: a\u00a0review and update. Expert Opin Drug Saf 10:373\u2013387","journal-title":"Expert Opin Drug Saf"},{"key":"1059_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","volume":"14","author":"C-Y Wang","year":"2008","unstructured":"Wang\u00a0C\u2011Y, Liu\u00a0P\u2011Y, Liao\u00a0JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14:37\u201344","journal-title":"Trends Mol Med"},{"key":"1059_CR28","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1038\/s41598-020-58668-2","volume":"10","author":"SA Grunwald","year":"2020","unstructured":"Grunwald SA, Popp O, Haafke S, Jedraszczak N, Grieben U, Saar K, Patone G, Kress W, Steinhagen-Thiessen E, Dittmar G, Spuler S (2020) Statin-induced myopathic changes in primary human muscle cells and reversal by a\u00a0prostaglandin F2 alpha analogue. Sci Rep 10:2158","journal-title":"Sci Rep"},{"key":"1059_CR29","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson\u00a0RS, Baker\u00a0SK, Jacobson\u00a0TA, Kopecky\u00a0SL, Parker\u00a0BA (2014) An assessment by the Statin Muscle Safety Task Force: 2014 update. J\u00a0Clin Lipidol 8:S58\u2013S71","journal-title":"J Clin Lipidol"},{"key":"1059_CR30","unstructured":"(2020) Clinical drug interaction studies\u2014Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Zugegriffen: article online"},{"key":"1059_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.7326\/0003-4819-158-12-201306180-00004","volume":"158","author":"AM Patel","year":"2013","unstructured":"Patel\u00a0AM, Shariff\u00a0S, Bailey\u00a0DG, Juurlink\u00a0DN, Gandhi\u00a0S, Mamdani\u00a0M, Gomes\u00a0T, Fleet\u00a0J, Hwang\u00a0YJ, Garg\u00a0AX (2013) Statin toxicity from macrolide antibiotic coprescription: a\u00a0population-based cohort study. Ann Intern Med 158:869\u2013876","journal-title":"Ann Intern Med"},{"key":"1059_CR32","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes\u00a0ES, Thompson\u00a0PD, Corsini\u00a0A, Vladutiu\u00a0GD, Raal\u00a0FJ, Ray\u00a0KK, Roden\u00a0M, Stein\u00a0E, Tokg\u00f6zo\u011flu\u00a0L, Nordestgaard\u00a0BG, Bruckert\u00a0E, De Backer\u00a0G, Krauss\u00a0RM, Laufs\u00a0U, Santos\u00a0RD, Hegele\u00a0RA, Hovingh\u00a0GK, Leiter\u00a0LA, Mach\u00a0F, M\u00e4rz\u00a0W, Newman\u00a0CB, Wiklund\u00a0O, Jacobson\u00a0TA, Catapano\u00a0AL, Chapman\u00a0MJ, Ginsberg\u00a0HN, Stroes\u00a0E, Thompson\u00a0PD, Corsini\u00a0A, Vladutiu\u00a0GD, Raal\u00a0FJ, Ray\u00a0KK, Roden\u00a0M, Stein\u00a0E, Tokg\u00f6zo\u011flu\u00a0L, Nordestgaard\u00a0BG, Bruckert\u00a0E, Krauss\u00a0RM, Laufs\u00a0U, Santos\u00a0RD, M\u00e4rz\u00a0W, Newman\u00a0CB, Chapman\u00a0JM, Ginsberg\u00a0HN, Chapman\u00a0JM, Ginsberg\u00a0HN, De Backer\u00a0G, Catapano\u00a0AL, Hegele\u00a0RA, Kees Hovingh\u00a0G, Jacobson\u00a0TA, Leiter\u00a0L, Mach\u00a0F, Wiklund\u00a0O (2015) Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart\u00a0J 36:1012\u20131022","journal-title":"Eur Heart J"},{"key":"1059_CR33","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.jacc.2017.07.767","volume":"70","author":"BA Taylor","year":"2017","unstructured":"Taylor\u00a0BA, Sanchez\u00a0RJ, Jacobson\u00a0TA, Chibedi-De-Roche\u00a0D, Manvelian\u00a0G, Baccara-Dinet\u00a0MT, Khan\u00a0I, Rosenson\u00a0RS (2017) Application of the Statin-associated muscle symptoms-clinical index to a\u00a0randomized trial on Statin Myopathy. J\u00a0Am Coll Cardiol 70:1680\u20131681","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/17482960802031092","volume":"9","author":"L Zinman","year":"2008","unstructured":"Zinman\u00a0L, Sadeghi\u00a0R, Gawel\u00a0M, Patton\u00a0D, Kiss\u00a0A (2008) Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 9:223\u2013228","journal-title":"Amyotroph Lateral Scler"},{"key":"1059_CR35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/bmj.308.6928.588","volume":"308","author":"MA Al-Jubouri","year":"1994","unstructured":"Al-Jubouri\u00a0MA, Briston\u00a0PG, Sinclair\u00a0D, Chinn\u00a0RH, Young\u00a0RM (1994) Lesson of the week: myxoedema revealed by simvastatin induced myopathy. BMJ 308:588\u2013588","journal-title":"BMJ"},{"key":"1059_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/1947-2714.153919","volume":"7","author":"M Khayznikov","year":"2015","unstructured":"Khayznikov\u00a0M, Hemachrandra\u00a0K, Pandit\u00a0R, Kumar\u00a0A, Wang\u00a0P, Glueck\u00a0CJ (2015) Statin intolerance because of Myalgia, Myositis, Myopathy, or Myonecrosis can in most cases be safely resolved by vitamin D supplementation. N\u00a0Am J Med Sci 7:86\u201393","journal-title":"N Am J Med Sci"},{"key":"1059_CR37","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"R Haynes","year":"2013","unstructured":"Haynes\u00a0R, Jiang\u00a0L, Hopewell\u00a0JC, Li\u00a0J, Chen\u00a0F, Parish\u00a0S, Landray\u00a0MJ, Collins\u00a0R, Armitage\u00a0J, Collins\u00a0R, Armitage\u00a0J, Baigent\u00a0C, Chen\u00a0Z, Landray\u00a0M, Chen\u00a0Y, Jiang\u00a0L, Pedersen\u00a0T, Landray\u00a0M, Bowman\u00a0L, Chen\u00a0F, Hill\u00a0M, Haynes\u00a0R, Knott\u00a0C, Rahimi\u00a0K, Tobert\u00a0J, Sleight\u00a0P, Simpson\u00a0D, Parish\u00a0S, Baxter\u00a0A, Lay\u00a0M, Bray\u00a0C, Wincott\u00a0E, Leijenhorst\u00a0G, Skattebol\u00a0A, Moen\u00a0G, Mitchel\u00a0Y, Kuznetsova\u00a0O, Macmahon\u00a0S, Kjekshus\u00a0J, Hill\u00a0C, Lam\u00a0TH, Sandercock\u00a0P, Peto\u00a0R, Hopewell\u00a0JC (2013) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart\u00a0J 34:1279\u20131291","journal-title":"Eur Heart J"},{"key":"1059_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.amjmed.2008.08.033","volume":"122","author":"RC Neal","year":"2009","unstructured":"Neal\u00a0RC, Ferdinand\u00a0KC, Ycas\u00a0J, Miller\u00a0E (2009) Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med 122:73\u201378","journal-title":"Am J Med"},{"key":"1059_CR39","first-page":"35","volume":"73","author":"C-Y Liu","year":"2010","unstructured":"Liu\u00a0C\u2011Y, Lai\u00a0Y\u2011C, Wu\u00a0Y\u2011C, Tzeng\u00a0C\u2011H, Lee\u00a0S\u2011D (2010) Macroenzyme creatine kinase in the era of modern laboratory. Medicine 73:35\u201339","journal-title":"Medicine"},{"key":"1059_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jama.2015.1335","volume":"313","author":"CB Newman","year":"2015","unstructured":"Newman\u00a0CB, Tobert\u00a0JA (2015) Statin intolerance: reconciling clinical trials and clinical experience. JAMA 313:1011\u20131012","journal-title":"JAMA"},{"key":"1059_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","volume":"137","author":"PS Phillips","year":"2002","unstructured":"Phillips\u00a0PS, Haas\u00a0RH, Bannykh\u00a0S, Hathaway\u00a0S, Gray\u00a0NL, Kimura\u00a0BJ, Vladutiu\u00a0GD, England\u00a0JD (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581\u2013585","journal-title":"Ann Intern Med"},{"key":"1059_CR42","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","volume":"389","author":"A Gupta","year":"2017","unstructured":"Gupta\u00a0A, Thompson\u00a0D, Whitehouse\u00a0A, Collier\u00a0T, Dahlof\u00a0B, Poulter\u00a0N, Collins\u00a0R, Sever\u00a0P (2017) Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial&#x2014;Lipid-Lowering Arm (ASCOT-LLA): a\u00a0randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389:2473\u20132481","journal-title":"Lancet"},{"key":"1059_CR43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","volume":"15","author":"BA Taylor","year":"2018","unstructured":"Taylor\u00a0BA, Thompson\u00a0PD (2018) Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics 15:1006\u20131017","journal-title":"Neurotherapeutics"},{"key":"1059_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ijcard.2016.04.003","volume":"214","author":"MJ Korhonen","year":"2016","unstructured":"Korhonen\u00a0MJ, Pentti\u00a0J, Hartikainen\u00a0J, Kivim\u00e4ki\u00a0M, Vahtera\u00a0J (2016) Somatic symptoms of anxiety and nonadherence to statin therapy. Int J Cardiol 214:493\u2013499","journal-title":"Int J Cardiol"},{"key":"1059_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","volume":"31","author":"RS Rosenson","year":"2017","unstructured":"Rosenson\u00a0RS, Miller\u00a0K, Bayliss\u00a0M, Sanchez\u00a0RJ, Baccara-Dinet\u00a0MT, Chibedi-De-Roche\u00a0D, Taylor\u00a0B, Khan\u00a0I, Manvelian\u00a0G, White\u00a0M, Jacobson\u00a0TA (2017) The Statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther 31:179\u2013186","journal-title":"Cardiovasc Drugs Ther"},{"key":"1059_CR46","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","volume":"70","author":"RS Rosenson","year":"2017","unstructured":"Rosenson\u00a0RS, Baker\u00a0S, Banach\u00a0M, Borow\u00a0KM, Braun\u00a0LT, Bruckert\u00a0E, Brunham\u00a0LR, Catapano\u00a0AL, Elam\u00a0MB, Mancini\u00a0GBJ, Moriarty\u00a0PM, Morris\u00a0PB, Muntner\u00a0P, Ray\u00a0KK, Stroes\u00a0ES, Taylor\u00a0BA, Taylor\u00a0VH, Watts\u00a0GF, Thompson\u00a0PD (2017) Optimizing cholesterol treatment in patients with muscle complaints. J\u00a0Am Coll Cardiol 70:1290\u20131301","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10557-017-6743-0","volume":"31","author":"K Awad","year":"2017","unstructured":"Awad\u00a0K, Mikhailidis\u00a0DP, Toth\u00a0PP, Jones\u00a0SR, Moriarty\u00a0P, Lip\u00a0GYH, Muntner\u00a0P, Catapano\u00a0AL, Pencina\u00a0MJ, Rosenson\u00a0RS, Rysz\u00a0J, Banach\u00a0M (2017) Efficacy and safety of alternate-day versus daily dosing of Statins: a\u00a0systematic review and meta-analysis. Cardiovasc Drugs Ther 31:419\u2013431","journal-title":"Cardiovasc Drugs Ther"},{"key":"1059_CR48","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jacl.2018.03.080","volume":"12","author":"A Alfaddagh","year":"2018","unstructured":"Alfaddagh\u00a0A, Elajami\u00a0TK, Saleh\u00a0M, Elajami\u00a0M, Bistrian\u00a0BR, Welty\u00a0FK (2018) The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: A secondary analysis of a\u00a0randomized clinical trial. J\u00a0Clin Lipidol 12:937\u2013947.e2","journal-title":"J Clin Lipidol"},{"key":"1059_CR49","doi-asserted-by":"publisher","first-page":"e006981","DOI":"10.1161\/JAHA.117.006981","volume":"6","author":"A Alfaddagh","year":"2017","unstructured":"Alfaddagh\u00a0A, Elajami\u00a0TK, Ashfaque\u00a0H, Saleh\u00a0M, Bistrian\u00a0BR, Welty\u00a0FK (2017) Effect of eicosapentaenoic and docosahexaenoic acids added to Statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. J\u00a0Am Heart Assoc 6:e6981","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"1059_CR50","doi-asserted-by":"publisher","first-page":"e009835","DOI":"10.1161\/JAHA.118.009835","volume":"7","author":"H Qu","year":"2018","unstructured":"Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ (2018) Effects of coenzyme Q10 on Statin-induced Myopathy: an updated meta-analysis of randomized controlled trials. J\u00a0Am Heart Assoc 7(19):e009835. https:\/\/doi.org\/10.1161\/JAHA.118.009835","journal-title":"J\u00a0Am Heart Assoc"},{"key":"1059_CR51","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","volume":"106","author":"T Sudhop","year":"2002","unstructured":"Sudhop\u00a0T, L\u00fcTjohann\u00a0D, Kodal\u00a0A, Igel\u00a0M, Tribble\u00a0DL, Shah\u00a0S, Perevozskaya\u00a0I, Von Bergmann\u00a0K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943\u20131948","journal-title":"Circulation"},{"key":"1059_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson\u00a0RS, Hegele\u00a0RA, Fazio\u00a0S, Cannon\u00a0CP (2018) The evolving future of PCSK9 inhibitors. J\u00a0Am Coll Cardiol 72:314\u2013329","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR53","unstructured":"(2018) Evolocumab. https:\/\/www.g-ba.de\/downloads\/91-1385-354\/2018-09-06_Geltende-Fassung_Evolocumab_D-345.pdf. Zugegriffen: 1. Apr. 2020"},{"key":"1059_CR54","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray\u00a0KK, Wright\u00a0RS, Kallend\u00a0D, Koenig\u00a0W, Leiter\u00a0LA, Raal\u00a0FJ, Bisch\u00a0JA, Richardson\u00a0T, Jaros\u00a0M, Wijngaard\u00a0PLJ, Kastelein\u00a0JJP (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N\u00a0Engl J Med 382:1507\u20131519","journal-title":"N Engl J Med"},{"key":"1059_CR55","unstructured":"(2020) Nilemdo 180\u202fmg Filmtabletten \u2013 Zusammenfassung der Merkmale des Arzneimittels. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nilemdo-epar-product-information_de.pdf. Zugegriffen: 17. Nov. 2020"},{"key":"1059_CR56","unstructured":"(2020) Nustendi 180\u202fmg\/10\u202fmg Filmtabletten \u2013 Zusammenfassung der Merkmale des Arzneimittels. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200327147391\/anx_147391_de.pdf. Zugegriffen: 17. Nov. 2020"},{"key":"1059_CR57","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray\u00a0KK, Bays\u00a0HE, Catapano\u00a0AL, Lalwani\u00a0ND, Bloedon\u00a0LT, Sterling\u00a0LR, Robinson\u00a0PL, Ballantyne\u00a0CM (2019) Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N\u00a0Engl J Med 380:1022\u20131032","journal-title":"N Engl J Med"},{"key":"1059_CR58","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg\u00a0AC, Leiter\u00a0LA, Stroes\u00a0ESG, Baum\u00a0SJ, Hanselman\u00a0JC, Bloedon\u00a0LT, Lalwani\u00a0ND, Patel\u00a0PM, Zhao\u00a0X, Duell\u00a0PB (2019) Effect of bempedoic acid vs placebo added to maximally tolerated Statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease. JAMA 322:1780","journal-title":"JAMA"},{"key":"1059_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne\u00a0CM, Banach\u00a0M, Mancini\u00a0GBJ, Lepor\u00a0NE, Hanselman\u00a0JC, Zhao\u00a0X, Leiter\u00a0LA (2018) Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 277:195\u2013203","journal-title":"Atherosclerosis"},{"key":"1059_CR60","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky\u00a0SL, Newton\u00a0RS, Day\u00a0EA, Ford\u00a0RJ, Lhotak\u00a0S, Austin\u00a0RC, Birch\u00a0CM, Smith\u00a0BK, Filippov\u00a0S, Groot\u00a0PHE, Steinberg\u00a0GR, Lalwani\u00a0ND (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL\u2011C and attenuates atherosclerosis. Nat Commun 7:13457","journal-title":"Nat Commun"},{"issue":"7","key":"1059_CR61","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG (2019) Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and Statin intolerance. J\u00a0Am Heart Assoc 8(7):e011662. https:\/\/doi.org\/10.1161\/JAHA.118.011662","journal-title":"J\u00a0Am Heart Assoc"},{"key":"1059_CR62","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne\u00a0CM, Laufs\u00a0U, Ray\u00a0KK, Leiter\u00a0LA, Bays\u00a0HE, Goldberg\u00a0AC, Stroes\u00a0ES, MacDougall\u00a0D, Zhao\u00a0X, Catapano\u00a0AL (2020) Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiolog 27:593\u2013603","journal-title":"Eur J Prev Cardiolog"},{"key":"1059_CR63","doi-asserted-by":"publisher","first-page":"e1003121","DOI":"10.1371\/journal.pmed.1003121","volume":"17","author":"AFG Cicero","year":"2020","unstructured":"Cicero\u00a0AFG, Fogacci\u00a0F, Hernandez\u00a0AV, Banach\u00a0M (2020) Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med 17:e1003121","journal-title":"PLoS Med"},{"key":"1059_CR64","unstructured":"(2016) Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). NCT02993406. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406. Zugegriffen: 22. Aug. 2020"},{"issue":"8","key":"1059_CR65","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","volume":"43","author":"AFG Cicero","year":"2020","unstructured":"Cicero AFG, Pontremoli R, Fogacci F, Viazzi F, Borghi C (2020) Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf 43(8):727\u2013736. https:\/\/doi.org\/10.1007\/s40264-020-00931-6","journal-title":"Drug Saf"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01059-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01059-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01059-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T11:03:28Z","timestamp":1627038208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01059-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01059-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"4 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>U.\u00a0Kassner<\/b>: A.\u00a0Finanzielle Interessen: Honorar f\u00fcr Vortr\u00e4ge und Advisory Boards: Alexion, Amgen, Sanofi, Berlin Chemie, Synlab Academy, Fresenius Medical Care, Amryt. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: angestellte Fach\u00e4rztin f\u00fcr Allgemeinmedizin, Institut f\u00fcr Endokrinologie und Ern\u00e4hrungsmedizin, Stoffwechselcentrum, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Campus Virchow | Mitgliedschaften: EAS, D.A.C.H. Gesellschaft f\u00fcr Pr\u00e4vention, DGFF. <b>S.\u00a0Grunwald<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Deutsche Forschungsgesellschaft, Klinische Forschergruppe KFO192\/2.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte wissenschaftliche Mitarbeiterin der Charit\u00e9 und im Projekt \u00fcber Statine (01.10.2010\u201314.11.2019), Angestellte, Berliner Institut f\u00fcr Gesundheitsforschung (BIH) im Technologietransfer (seit: 15.11.2019).<b> D.\u00a0Spira<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Sanofi, DM-finanzierte Studie. \u2013\u00a0Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Sanofi, Fresenius, Urgo, Boehringer\/Lilly, Roche, Berlin Chemie.\u00a0\u2013 Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Carl Zeiss Meditec, Amgen, Siemens Healthineers, Novartis. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: angestellter Internist, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Allgemeines Gesundheitszentrum der Charit\u00e9.<b> N.\u00a0Buchmann<\/b>: A.\u00a0Finanzielle Interessen: kein finanzieller Interessenkonflikt.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: \u00e4rztlicher Mitarbeiter, Medizinische Klinik f\u00fcr Kardiologie, Abteilung f\u00fcr Kardiologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Campus Benjamin Franklin, Berlin | Mitgliedschaften: DGFF (Lipidologe), DGEM (Ern\u00e4hrungsmediziner).<b> T.\u00a0Bobbert<\/b>: A.\u00a0Finanzielle Interessen: Vortr\u00e4ge: Daiichi, Boehringer, MSD, Novartis, AstraZeneca, Novo Nordisk, Lilly, Sanofi. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Klinik f\u00fcr Endokrinologie und Stoffwechselmedizin | Mitgliedschaften: DDG, Lipidliga, Sport\u00e4rztebund Berlin-Brandenburg.<b> E.\u00a0Gazzerro<\/b>: A.\u00a0Finanzielle Interessen: kein finanzieller Interessenkonflikt.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: verantwortl. Ober\u00e4rztin, Fach\u00e4rztin an der Hochschulambulanz f\u00fcr Muskelkrankheiten, ECRC, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Campus Buch, Charit\u00e9 \u2013 Universit\u00e4tsmedizin und Max-Delbr\u00fcck-Centrum, Berlin.<b> T.\u00a0Hollstein<\/b>: A.\u00a0Finanzielle Interessen: Unterst\u00fctzung f\u00fcr Kongressreise: Sanofi, Amgen, Referentenhonorar: Daiichi Sankyo. \u2013\u00a0Aktien: Pfizer, Novartis, Bayer, Fresenius, Novo Nordisk, Siemens Healthcare.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, UKSH Kiel | Mitgliedschaft: D\u2011A-CH Gesellschaft.<b> S.\u00a0Spuler<\/b>: A.\u00a0Finanzielle Interessen: kein finanzieller Interessenkonflikt. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Abteilungsleitung Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Abt. f\u00fcr Muskelkrankheiten, Charit\u00e9 Campus Buch | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Muskelkrankheiten (DGM), American Society for Gene and Cell Therapy (ASGCT). <b>E.\u00a0Steinhagen-Thiessen<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung in Form geldwerter Leistungen f\u00fcr Personal: Fa. Sanofi.\u00a0\u2013 T\u00e4tigkeit als Referentin, Moderatorin: verschiedene Veranstaltungen, Honorar und Erstattung der Reisekosten: Fresenius, Sanofi, Akcea, Daiichi-Sankyo, Novartis. \u2013\u00a0Durchf\u00fchrung einer Schulung f\u00fcr Novartis-Mitarbeiter.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: emeritierte Professorin (Charite \u2013 Universit\u00e4tsmedizin Berlin), Seniorprofessur (Charite \u2013 Universit\u00e4tsmedizin Berlin), Gastprofessur (Universit\u00e4t Greifswald), sie bezieht ihre Pension, Angestellte (Werkvertrag, 10\u202f% T\u00e4tigkeit eines Facharztes, Universit\u00e4t Greifswald).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}